Immuneering Corporation (NASDAQ:IMRX – Get Free Report) has received an average recommendation of “Buy” from the seven brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have given a buy rating and two have assigned a strong buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $17.50.
A number of brokerages have commented on IMRX. Needham & Company LLC increased their price objective on shares of Immuneering from $11.00 to $18.00 and gave the company a “buy” rating in a research report on Monday, July 20th. Wall Street Zen lowered Immuneering from a “hold” rating to a “sell” rating in a report on Monday, July 20th. Oppenheimer reissued an “outperform” rating on shares of Immuneering in a research report on Monday, June 1st. UBS Group set a $14.00 target price on Immuneering in a research note on Thursday, August 6th. Finally, Chardan Capital raised Immuneering to a “strong-buy” rating in a report on Monday, August 3rd.
Read Our Latest Research Report on Immuneering
Immuneering Stock Performance
Immuneering (NASDAQ:IMRX – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.01). Sell-side analysts predict that Immuneering will post -1.09 earnings per share for the current year.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of IMRX. WINTON GROUP Ltd acquired a new stake in shares of Immuneering in the 2nd quarter valued at about $86,000. Integrated Wealth Concepts LLC purchased a new position in Immuneering during the 2nd quarter worth approximately $34,000. Corient Private Wealth LP acquired a new position in Immuneering during the second quarter worth approximately $385,000. Focus Financial Network Inc. acquired a new position in Immuneering during the second quarter worth approximately $62,000. Finally, PVG Asset Management Corp acquired a new position in Immuneering during the first quarter worth approximately $773,000. Institutional investors and hedge funds own 67.65% of the company’s stock.
About Immuneering
Immuneering Corporation is a clinical-stage biotechnology company focused on developing medicines for cancer patients with limited treatment options. The company’s research centers on the mitogen-activated protein kinase (MAPK) pathway, a cellular signaling network frequently altered in solid tumors, including cancers driven by RAS mutations.
Immuneering’s lead product candidate is IMM-1-104, an oral therapy designed to provide deep and sustained inhibition of the MAPK pathway while using intermittent exposure to help normal cells recover.
Recommended Stories
- Five stocks we like better than Immuneering
- NVIDIA Just Named AI’s Next Bottleneck—And These 3 Stocks Sit Right In It
- Gold Has Gone Sideways, But These 3 Stocks Haven’t
- The AI Bottleneck Is Not Chips Anymore and 3 Pipeline Stocks Are Cashing In
- These 3 Stocks Under $20 Have Wall Street Looking Past the Share Price
Receive News & Ratings for Immuneering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuneering and related companies with MarketBeat.com's FREE daily email newsletter.
